Skip to main content
Equibles

GLAND · Gland Pharma Limited · Financials

Use GLAND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLAND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
3,334.70 INR +27.20 (+0.82%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 11.05K Avg daily vol (3M) 250.76K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
64.31B +14.5%
FY2026 Revenue FY2021–FY2026
Net Income
10.27B +47.1%
FY2026 Net Income FY2021–FY2026
Operating Cash Flow
10.31B +12.8%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021
INR 70.72B 64.31B 56.17B 56.65B 36.25B 44.01B 34.63B
INR 4.43B 4.24B 3.78B 3.45B 1.47B 1.1B 987.8M
INR 254.59M 332.79M 420M 262M 74.47M 52.42M 34.11M
INR 17.34B 14.65B 10.63B 11.33B 10.55B 16.19B 13.35B
INR 4.98B 4.37B 3.64B 3.6B 2.74B 4.07B 3.38B
INR 12.36B 10.27B 6.99B 7.72B 7.81B 12.12B 9.97B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 6.26B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.